| Financial Information Relating to Reportable Segments |
Following is financial
information relating to the Company’s reportable segments (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Quarter
Ended |
|
|
Nine Months
Ended |
|
| |
|
March 31, |
|
|
March 31, |
|
| |
|
2012 |
|
|
2011 |
|
|
2012 |
|
|
2011 |
|
|
External sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
78,180 |
|
|
$ |
71,120 |
|
|
$ |
220,291 |
|
|
$ |
197,241 |
|
|
Hematology
|
|
|
5,441 |
|
|
|
5,151 |
|
|
|
15,588 |
|
|
|
14,683 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net
sales
|
|
$ |
83,621 |
|
|
$ |
76,271 |
|
|
$ |
235,879 |
|
|
$ |
211,924 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before income
taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
45,442 |
|
|
$ |
44,911 |
|
|
$ |
123,304 |
|
|
$ |
121,324 |
|
|
Hematology
|
|
|
2,037 |
|
|
|
1,947 |
|
|
|
5,636 |
|
|
|
5,296 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment earnings before
income taxes
|
|
|
47,479 |
|
|
|
46,858 |
|
|
|
128,940 |
|
|
|
126,620 |
|
|
Unallocated corporate
expenses and equity method investee losses
|
|
|
(4,274 |
) |
|
|
(1,474 |
) |
|
|
(7,362 |
) |
|
|
(4,610 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated earnings
before income taxes
|
|
$ |
43,205 |
|
|
$ |
45,384 |
|
|
$ |
121,578 |
|
|
$ |
122,010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|